Prevalence and Awareness of CKD
• 15 % of USA population (25 million) • 5 million with eGFR < 30 ml/min
• Awareness
• 24%
• Projected 600,000 on dialysis by 2010 • Family members of dialysis patients 47% CKD • 16% Australia with CKD • 0.78-1.1% poor Indian states with CKD
• 7%
• 11%
Prevalence of ESRD and Economics
Life expectancy at birth in relation to GDP per capita (Daniels et al ) Cornerstone of Proteinuric CKD Management
•Blood Pressure Control: < 130/80 or 125/75
•ARBs/ACEi (Escape)
•Optimal Glycaemic Control: HbA1c < 7.5%
Acidosis and Protein Energy Wasting
• Anorexia • Metabolic acidosis induces endothelin and promotes progression of renal failure in rats. Aims:
Effect of correction of acidosis in patients with CKD stage 4/5 on the rate of decline of eGFR, development of ESRD and nutritional status.
Study Design:
Open label prospective randomised control trial with two years follow up.
Location: Location:
Pre dialysis clinic, Royal London Hospital, London, UK.
Study Population:
Patients aged 18-75 years with CKD stage 4/5 and mild metabolic acidosis (HCO3 < 21 and > 16 mmol/l).
Exclusion Criteria:
Chronic sepsis, uncontrolled HTN, Fluid overload/ CHF, Steroid therapy, Morbid obesity, Cognitive impairment. 
Study Parameters

